Vaccine contraindications

Employees previously completed the hepatitis B vaccination series Immunity confirmed through antibody testing Vaccine contraindicated for medical reasons Eollowing participation in a prescreening plan Employees who decline the vaccination... 

On occasion, it may be necessary to postpone the regular immunization schedule, particularly for children. This is of special concern to parents. The decision to delay immunization because of illness or for other reasons must be discussed with the primary health care provider. However, the decision to administer or delay vaccination because of febrile illness (illness causing an elevated temperature) depends on the severity of the symptoms and the specific disorder. In general, all vaccines can be administered to those with minor illness, such as a cold virus and to those with a low-grade fever. However, moderate or severe febrile illness is a contraindication. hi instances of moderate or severe febrile illness, vaccination is done as soon as the acute phase of... 

For additional information about vaccines, vaccine supply, and contraindications for immunization, please visit the National Immunization Program Web site at www.cdc.gov/nip or call the National Immunization Hotline at (800) 232-2522 (English) or (800) 232-0233 (Spanish). 

The primary course of DTP protection consists of three doses of a combined vaccine, each dose separated by at least 1 month and commencing not earlier than 2 months of age. In such combinations the pertussis component ofthe vaccine acts as an additional adjuvant for the toxoid components. Monovalent pertussis and tetanus vaccines, and combined vaccines lacking the pertussis component (DT) are available. If pertussis vaccination is contraindicated or refused then DT vaccine alone should be offered. The primary course of pertussis vaccination is considered sufficient to confer life-long protection, especially since the mortality associated with disease declines markedly after infancy. The risks associated with tetanus and diphtheria infection persist... 

Following hematopoietic stem cell transplantation the patient will need virtually all routine vaccines to be administered again however, the patient will not be able to mount an adequate response for 6 to 12 months post-transplant. Diphtheria, tetanus, acellular pertussis, Haemophilus influenzae type b, hepatitis B, pneumococcal, and inactivated poliovirus should be given at 12,14, and 24 months post-hematopoietic stem cell transplantation. Inactivated influenza vaccine should be given yearly, starting 6 months after transplant. Measles, mumps and rubella can be given 2 years after transplant and varicella vaccine is contraindicated.16... 

This schedule indicates the recommended ages for routine administration of currently licensed childhood vaccines, as of December 1, 2006, for children aged 7-18 years, Additional information is available at http //www.cdc.gov/nip/recs/child-schedule.htm Any dose not administered at the recommended age should be administered at any subsequent visit, when indicated and feasible. Additional vaccines may be licensed and recommended during the year. Licensed combination vaccines may be used whenever any components of the combination are indicated and other components of the vaccine are not contraindicated and if approved by the Food... 

These schedules indicate the recommended age groups and medical indications for which administration of currently licensed vaccines is commonly indicated for adults ages 19 years and older, as of October 1,2007, Licensed combination vaccines maybe used whenever any components of toe combination are indicated and when the vaccine s other components are not contraindicated. For detailed recommendations on all vaccines, including those used primarily for travelers or that are issued during toe year, consult the manufacturers package inserts and the complete statements from toe Advisory Committee on Immunization Practices (wmcdc.gov/vaccines/pubs/acip-list.htm). ... 

A single dose of zoster vaccine is recommended for adults aged >60 years regardless of whether they report a prior episode of herpes zoster. Persons with chronic medical conditions may be vaccinated unless a contraindication or precaution exists for their condition. 

General contraindications to vaccine administration include a history of anaphylactic reaction to a previous dose or an unexplained encephalopathy occurring within 7 days of a dose of pertussis vaccine. Immunosuppression and pregnancy are temporary contraindications to live vaccines. Whenever possible, transplant patients should be immunized before transplantation. Live vaccines generally are not given after transplantation. 

IPV is given to children aged 2, 4, and 6 to 18 months and 4 to 6 years. Primary poliomyelitis immunization is recommended for all children and young adults up to age 18 years. Allergies to any component of IPV, including streptomycin, polymyxin B, and neomycin, are contraindications to vaccine use. 

Although the vaccine has not been associated with congenital rubella syndrome, its use in pregnancy is contraindicated. Women should be counseled not to become pregnant for 4 weeks after vaccination. 

The vaccine is contraindicated in immunosuppressed or pregnant patients. Children with asymptomatic or mildly symptomatic HIV should receive two doses of varicella vaccine 3 months apart. 

Vaccines Yes. Wyeth Vaccine, called VIG or vaccinia immune globulin, one dose by scarification. (Pre- and post-exposure vaccination recommended if greater than three years passed since last vaccine.) Persons who are pregnant, have clinical immunosuppression (such as persons who have undergone heart and other transplant operations and take medicines to control rejection of their new, transplanted organ), eczema, and/or leukemia/ lymphoma would be contraindicated for such vaccine. As one example, the fatality rate for immunosuppressed persons taking such vaccine could be as high as 75 percent or more. 

CDC, Update vaccine side effects, adverse reactions, contraindications, and precautions reommendations of the advisory committee on immunization practices (ACIP), MMWR, 45(RR12 001), September 6,1996. 

Prophylaxis - Chemoprophylaxis against influenza A virus infection when early vaccination is not feasible or when the vaccine is contraindicated or not available. Following... 

Prophylaxis - Start in anticipation of contact or as soon as possible after exposure. Use daily for at least 10 days following a known exposure. The infectious period extends from shortly before onset of symptoms to up to 1 week after. Because amantadine does not appear to suppress antibody response, it can be used in conjunction with inactivated influenza A virus vaccine until protective antibody responses develop administerfor 2 to 4 weeks after vaccine has been given. When the vaccine is unavailable or contraindicated, give amantadine for the duration of known influenza A in the community because of repeated and unknown exposure. 

Etanercept therapy should not be initiated in patients with active infection. If an infection develops in a person taking etanercept, he or she should be closely monitored. If a serious infection or sepsis occurs, the drug should be discontinued. Etanercept should be used with caution in individuals who have conditions predisposing them to serious infection (e.g., uncontrolled diabetes, hematological abnormalities). Data on drug interactions are limited. Live virus vaccines are contraindicated because of the potential for secondary transmission of the infection by the vaccine. Myelo-suppressive antirheumatic agents have been associated with pancytopenia in some patients treated with etanercept. 

Infliximab should not be given to individuals with known hypersensitivity to murine proteins. As with etanercept, precautions for the prevention of serious infections must be taken, and live virus vaccines are contraindicated. 

The Centers for Disease Control s (CDC) Immunization Practices Advisory Committee recommends annual vaccination as the method of choice in the prevention of influenza infection. However, when vaccination is contraindicated or early vaccination is not possible, amantadine and rimantadine are effective prophylactic agents that have been shown to protect approximately 70 to 90% of patients from influenza A infection. Since these drugs do not prevent the host immune response to influenza A, they may be used to prevent infection during the 2- to 4-week period required to develop immunity following vaccination. An additional use of amantadine, unrelated to its antiviral activity, is in the therapy of Parkinson s disease (see Chapter 31). 

Zanamivir is contraindicated in individuals with severe or decompensated chronic obstructive lung disease or asthma because it has not been shown to be effective in these individuals and can cause serious adverse pulmonary reactions. Individuals with mild to moderate asthma may have a decline in lung function when taking zanamivir. The safety and efficacy of this medication have not been determined in individuals with severe renal insufficiency. No clinically significant drug interactions have been reported. Zanamivir does not decrease the effectiveness of the influenza vaccine. 

Contraindications Hypersensitivity to corticosteroids, administration of live virus vaccine, peptic ulcers (except in life-threatening situations), systemic fungal infection... 

Contraindications Administration of live virus vaccines, systemic fungal infection... 

Contraindications Administration of live virus vaccines, especially smallpox vaccine hypersensitivity to corticosteroids or tartrazine peptic ulcer disease (except life-threatening situations) systemic fungal infection Topical Marked circulation impairment... 

Systemic reactions, such as moderate fever, occur in 3% to 5% of those receiving vaccines. Very rarely, high fever, febrile seizures, persistent crying spells, and hypotonic hyporesponsive episodes occur after vaccination. There are only two absolute contraindications to pertussis administration an immediate anaphylactic reaction to a previous dose or encephalopathy within 7 days of a previous dose, with no evidence of other cause. 

Two types of trivalent poliovirus vaccines are currently licensed for distribution in the United States an enhanced inactivated vaccine (IPV) and a live attenuated, oral vaccine (OPV). IPV is the recommended vaccine for the primary series and booster dose for children in the United States, whereas OPV is recommended in areas of the world that have circulating pohovirus. IPV is given to children aged 2, 4, and 6 to 18 months and 4 to 6 years. Primary poliomyelitis immunization is recommended for all children and young adults up to age 18 years. Allergies to any component of IPV, including streptomycin, polymyxin B, and neomycin, are contraindications to vaccine use. 

---